Two devices may be better than one for obesity treatment

NCT ID NCT05559866

Completed Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether combining two endoscopic procedures—Hybrid Argon Plasma Coagulation (HAPC) and Endoscopic Sleeve Gastroplasty (ESG)—is safer and more effective than ESG alone for weight loss. The trial included 45 adults with obesity (BMI 30–40) who had not succeeded with non-surgical methods. The main goal was to see if the combination made the sutures last longer at 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hybrid Argon Plasma Coagulation (HAPC) and Endoscopic Sleeve Gastroplasty (ESG) devices
What this could lead to: If successful, this combination could make endoscopic weight-loss procedures more durable and effective for people with obesity.
What could go wrong: This is a small, single-center trial with only 45 participants. The primary outcome is about suture durability, not long-term weight loss, so results may not translate to lasting benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.